Jazz Pharmaceuticals Plc Aktie News

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Cancer Network® Guidelines for SCLC For U.S. media and investors only DUBLIN , Oct. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administr...

The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer.

Jazz Pharmaceuticals (JAZZ) receives a BUY rating, driven by strong DUET trial results for Xywav in narcolepsy and idiopathic hypersomnia. JAZZ's growth is anchored by Xywav and Epidiolex, both generating robust sales and supporting future oncology pipeline expansion. Recent clinical milestones, upcoming FDA decisions, and a well-executed leadership transition position JAZZ for long-term value ...

20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic hypersomnia For U.S. media and investors only DUBLIN , Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new ...

Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors only DUBLIN , Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncolog...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit...

DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will participate in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m.

DUBLIN , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m.